ClinicalTrials.gg
CompletedNCT05556863Updated Mar 27, 2024

Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

A Phase 1 interventional study of ELA026 and ELA026 in Healthy Volunteers, sponsored by Electra Therapeutics Inc.. Completed at 2 sites in 2 countries. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Electra Therapeutics Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Nov 2023, 2 years 11 months ago, and no results have been posted to the registry.
  • Registered 11 months after the study started (first participant enrolled Oct 2021, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.

Read the detailed description

This is a multi-center, Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, PK, and PD of ELA026 following single and multiple IV and/or SC dose administration in healthy adult volunteers, including a subgroup of Japanese volunteers.

The study will consist of 2 parts:

  • Part 1: single ascending doses (SAD) in up to 11 SAD cohorts plus a Japanese cohort
  • Part 2: multiple doses (MD) up to 6 MD cohorts
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Electra Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-Japanese subjects 19 to 60 years of age. Japanese subjects 20 to 60 years of age.
  2. Must be in good general health.
  3. No abnormal laboratory values during screening.
  4. of 18 - 32 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Clinical diagnosis or laboratory evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic disease at Screening.
  2. Diagnosed with any form of (except basal cell carcinoma, fully removed).
  3. immunodeficiency or autoimmunity assessed by medical history and/or laboratory test results.
  4. Active or latent tuberculosis (TB), regardless of treatment history,
  5. Positive drug abuse test.
  6. Positive , , test results.
  7. Clinically significant test results.
  8. Clinically significant vital sign results.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Part 1: Single Ascending Dose

    Cohort 1 Single dose: 0.001 mg/kg IV Cohorts 2 - 11 Single dose: dose level and route (IV or SC) to be determined Japanese Cohort Single dose: dose level and route (IV or SC) to be determined

    Drug: ELA026

  • Experimental
    Part 2: Multiple Ascending Dose

    Cohort 1 - 6 Multi-dose: dose level, route (IV or SC) and frequency to be determined

    Drug: ELA026

Interventions

  • DrugELA026

    Single dose of ELA026

  • DrugELA026

    Multiple doses of ELA026

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability].

    Time frame: By week 3

Secondary outcomes

  1. Plasma concentrations of ELA026

    Time frame: By week 3

  2. Change from baseline of monocytes levels.

    Time frame: By week 3

  3. Change from baseline of lymphocytes levels.

    Time frame: By week 3

  4. Presence of Anti-drug antibodies to ELA026

    Time frame: By week 3

  5. Comparison of ELA026 Maximum observed drug concentration (Cmax)

    Time frame: By week 3

  6. Comparison of ELA026 Area under the curve plasma concentration versus time curve (AUC)

    Time frame: By week 3

07

Study locations

2 sites
  • Celerion
    Lincoln, Nebraska 68502, United States
  • Medical University of Vienna
    Vienna, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Nov 2023, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2022
First posted
Sep 27, 2022
StartActual
Oct 18, 2021
Primary completionActual
Nov 20, 2023
CompletionActual
Nov 20, 2023
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05556863
Lead sponsor
Electra Therapeutics Inc.
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Oct 18, 2021
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Last update
Mar 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ipsoprubart

Start the discussion